Navigation Links
23ème congrès européen sur l'Hypertension et la Protection Cardiovasculaire
Date:6/25/2013

lope, Chef de l'Unité Hypertension à l'Hôpital du 12 Octobre de Madrid en Espagne, et investigateur principal de l'étude SEVITENSION. "Les études post-commercialisation telles que celle-ci fournissent des données importantes pour aider les médecins à choisir les meilleures options thérapeutiques afin de prendre en charge de manière plus efficace et plus pratique l'hypertension artérielle, et ainsi de mieux protéger les patients. Cette amélioration potentielle dans la prise en charge de l'HTA aidera les médecins à atteindre l'objectif ambitieux de contrôler la pression artérielle chez au moins 70% des patients hypertendus d'ici 2015."

Les médicaments tels que les inhibiteurs de l'enzyme de conversion de l'angiotensine (IEC) réduisent la pression artérielle en inhibant l'activité du système rénine-angiotensine (SRA). Une classe plus récente de médicaments antihypertenseurs, appelés antagonistes du récepteur de l'angiotensine (ARA II) réduit aussi la pression artérielle en inhibant le SRA, et offre l'avantage de provoquer moins d'effets secondaires que les IEC, notamment la toux.[7]

Daiichi Sankyo soutient activement la recherche sur les antihypertenseurs, et a développé toute une gamme de médicaments à base de l'ARA II olmésartan. Un de ces produits, l'association fixe olmésartan/amlodipine (Sevikar®), a été utilisée pour tenter de répondre à une question clinique importante : est-ce que l'association de deux médicaments composée d'un ARA II tel que l'olmésartan, et de l'amlodipine peut réduire la pression artérielle centrale aussi efficacement que l'association du périndopril et de l'amlodipine ? Cette question a &#
'/>"/>

SOURCE Daiichi Sankyo Europe GmbH
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
2. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
3. Global Leaders in Advanced Biofuels Industry Urge Congressional Leaders to Extend Critical Tax Provisions
4. Nation Must Invest in Biomedical Research/Health Workforce, AAHC President Tells Congress
5. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
7. ETEX Corporation to present at the 9th World Biomaterial Congress
8. Discovery Labs to Present AFECTAIR® Data at European Congress on Pediatric and Neonatal Ventilation
9. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
10. The Legends that Contributed to Silicon Valleys Eminence Assemble for Frost & Sullivans Growth, Innovation and Leadership 2012 Congress
11. BIOCOM Announces Endorsement in 52nd Congressional District Race
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Leading ... clinical study of its canine osteoarthritis stem cell product, currently under development for ... KS) and will be marketed in the US by Aratana. This product, termed ...
(Date:7/30/2015)... 2015 HIGHLIGHTS:Q2 2015 Results (all ... , Reported sales were $697 million compared to $701 ... organically by 8%, and changes in foreign currency exchange ... by 1%. , By business unit, organic sales ... 11% in SAFC Commercial. , Reported diluted EPS ...
(Date:7/29/2015)... 30, 2015 Sanofi, un ... ses résultats pour le premier semestre 2015. Le ... résultats. Visionner l,interview vidéo et lire ... Au sommaire de l,interview :  ... de croissance - Diabète ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), ... healthcare services, offering both facility-based and home-based post-acute ... the second quarter ended June 30, 2015. ... volume growth in both segments and an 11.0% ... President and Chief Executive Officer of HealthSouth. "While ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15
... operate efficiently and last a long time is a big ... the assembly line. The precious metal platinum has been the ... It is expensive, and it breaks down over time in ... University report a promising advance. They have created a unique ...
... MARINO, Calif. , May 24 Epeius Biotechnologies ... the study entitled "A Phase I/II Study of Intravenous Rexin-G ... ASCO Annual Meeting on June 6, 2010 . The ... , Chairman of the Cancer Institute and Bioethics Committee-Philippine General ...
... 24 Newport Corporation (Nasdaq: NEWP ) today announced that it ... 25, 2010 , at 3:30 pm Pacific time (6:30 pm ... of Loews Santa Monica Beach Hotel in Santa Monica, Calif. , ... The 25-minute presentation by Senior Vice President ...
Cached Biology Technology:Brown chemists report promising advance in fuel-cell technology 2Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010) 2Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010) 3Newport Corporation to Present at B. Riley & Co. Investor Conference Tomorrow, May 25 2
(Date:7/9/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/98rrmr/biometrics_for ... "Biometrics for Banking; Market & Technology Analysis, Adoption ... offering. The adoption for banking purposes ... the forecast is that by 2020 it will ... in delivering biometric systems to the banking industry. ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
(Date:7/8/2015)... The consumer products industry for innovative ... products such as wearables, smart wallets & other smart technology ... devices continues to rapidly grow.  Biometrics & Wearable Device Companies ... Google Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... (NASDAQ: GPRO ) and Baidu Inc. (NASDAQ: BIDU ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6
... 11, 2013 Men tend to store fat in the ... of hips or thighs. Women, on the other hand, are ... than in the belly. Why are women and men shaped ... worth investigating, says Steven R. Smith, M.D., director of the ...
... , An internationally recognized expert in viruses, Robert W. ... and chair and professor of medicine at the University ... $12 million project to develop new ways of predicting ... to anti-viral drugs and the human immune system. This ...
... plants is short. They grow for around three to four ... also limited, with plants only growing to about one-and-a-half to ... Molecular Biology and Applied Ecology IME in Mnster have located ... they can keep it forever young. The Mnster-based researchers discovered ...
Cached Biology News:How belly fat differs from thigh fat -- and why it matters 2Giant tobacco plants that stay young forever 2
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
Parathyroid Hormone Receptor 2 [PTHR2]...
... Zeba Desalt Spin Columns contain a proprietary ... offers exceptional desalting and protein-recovery characteristics compared ... as low as 25 g/ml of protein ... and > 95% retention of salts and ...
Biology Products: